Bladder Cancer : (Record no. 101200)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11137nam a22005293i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC4037419 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729130038.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2015 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118674857 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781118674840 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC4037419 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL4037419 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11111713 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaONFJC)MIL820104 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)917551850 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC280.B5 -- .B533 2015eb |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99462 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Lerner, Seth P. |
| 245 10 - TITLE STATEMENT | |
| Title | Bladder Cancer : |
| Remainder of title | Diagnosis and Clinical Management. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2015. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2015. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (445 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Title Page -- Copyright Page -- Contents -- List of contributors -- Preface -- Acknowledgments -- Part I Diagnosis and treatment of non-muscle-invasive bladder cancer -- Chapter 1 Pathology -- Benign urothelium -- Reactive urothelium -- Urothelial hyperplasia -- Urothelial dysplasia -- Flat urothelial carcinoma in situ (CIS) -- Papillary lesions -- Invasive urothelial carcinoma -- Carcinomas with divergent (aberrant) differentiation -- Squamous cell carcinoma -- Adenocarcinoma -- Small cell/neuroendocrine carcinoma -- Nested variant of urothelial carcinoma -- Lymphoepithelioma-like carcinoma -- Micropapillary carcinoma -- Sarcomatoid carcinoma -- Useful web links -- References -- Chapter 2 Risk stratification of high-grade Ta, CIS, and T1 urothelial carcinoma of the bladder -- Introduction -- Risk stratification -- Ta high-grade urothelial carcinoma of the bladder -- Carcinoma in situ -- T1 urothelial carcinoma of the bladder -- Non-surgical treatment options for BCG failure -- Early radical cystectomy -- References -- Chapter 3 Utility of urine biomarkers -- Introduction -- FDA-approved urine markers -- Useful web links -- Note -- References -- Chapter 4 Novel endoscopic techniques for the detection of bladder cancer -- Photodynamic diagnosis (PDD) -- Narrow band imaging -- Confocal laser endomicroscopy -- Optical coherence tomography -- Conclusions -- Useful web link -- References -- Chapter 5 Transurethral resection of bladder tumors -- Introduction -- Endoscopy and visualization of the bladder -- The first TURBT and the evolution of instrumentation -- Patient preparation -- Surgical technique -- Special situations for TURBT -- Efficacy of TURBT -- Other techniques -- Intravesical therapy -- Radical TURBT and bladder-sparing for muscle-invasive disease -- Conclusions -- Useful web links -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 6 Intravesical chemotherapy -- Introduction -- History of intravesical chemotherapy -- Intravesical chemotherapy -- Treatment outcome -- Complications/side effects -- Device-assisted intravesical chemotherapy -- Useful web links -- Note -- References -- Chapter 7 Intravesical immunotherapy -- Introduction -- History/development -- BCG mechanism of action -- Induction -- BCG and carcinoma in situ -- BCG prevention of recurrence -- BCG prevention of progression -- BCG maintenance -- BCG toxicity and treatment -- Alternative forms of immunotherapy -- Conclusion -- Useful web links -- References -- Chapter 8 HGT1 bladder cancer: Diagnosis and treatment -- Overview -- Diagnosis -- Follow-up -- Treatment -- Useful web links -- References -- Chapter 9 What to do when bacillus Calmette-Guérin fails -- Introduction -- Definition of BCG failure -- Treatment of BCG-refractory CIS -- Conclusion -- Useful web links -- References -- Part II T2-4 -- Chapter 10 Selection and perioperative management of patients undergoing radical cystectomy and urinary reconstruction -- Introduction -- Patient selection -- Pre-operative preparation -- Inpatient standardization and pathways (inpatient and beyond) -- Conclusions and future state - what do we need to work on? -- Useful web links -- References -- Chapter 11 Radical cystectomy: Techniques and outcomes -- Introduction -- Anatomy -- Diagnosis and staging -- Indications and treatment -- Perioperative management -- Post-operative management -- Pain management -- Discharge and post-operative care -- Extent of lymph node dissection -- Technique: radical cystectomy with extended pelvic lymph node dissection -- Outcomes -- Complications -- Conclusion -- Useful web link -- References -- Chapter 12 Cystectomy in the female patient -- Introduction -- Anterior exenteration and pelvic lymphadenectomy. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Surgical considerations in pre-operative planning of orthotopic diversions in female patients -- Functional aspects of orthotopic neobladder reconstruction in female patients -- Technique of anterior exenteration -- Risk of cancer recurrence in the urethra in women -- Incontinence, residual urine, and urinary retention after orthotopic neobladder reconstruction -- Follow-up of women with ileal neobladder placement -- Useful web links -- References -- Chapter 13 Laparoscopic/robotic radical cystectomy and urinary diversion: Outcomes -- Operative outcomes -- Post-operative outcomes -- Complications -- Oncologic outcomes -- Functional outcomes -- Useful web links -- References -- Chapter 14 Robotic assisted radical cystectomy and urinary diversion: Clinical trials -- Oncologic outcomes -- Surgical margin status -- Lymph node dissection -- Complications -- Randomized studies -- Conclusions -- Useful web links -- References -- Chapter 15 Role of extended lymphadenectomy -- The role of extended lymphadenectomy -- Lymphatic drainage of the bladder - historical and anatomic considerations -- Prognostic importance of lymph node status -- Extent of lymphadenectomy -- Outcomes based on the extent of lymphadenectomy -- Ongoing randomized studies evaluating the extent of lymphadenectomy -- Conclusions -- References -- Chapter 16 Management of the urethra in the cystectomy patient -- Introduction -- Incidence of urethral cancer following radical cystectomy -- Impact of urinary diversion type on metachronous urethral cancers -- Post radical cystectomy monitoring of the urethra -- Treatment for cancer of the retained urethra -- Conclusion -- Useful web links -- References -- Chapter 17 The role of radical cystectomy in patients with unresectable or regionally metastatic urothelial carcinoma of the bladder -- Introduction. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Pre-surgical versus neoadjuvant chemotherapy -- Outcomes of surgical consolidation after systemic chemotherapy -- Adjuvant radiation therapy -- Proposed clinical algorithm -- Conclusion -- Useful web links -- References -- Part III Primary bladder-sparing therapy -- Chapter 18 Radical transurethral resection -- Introduction -- Radical TURBT -- Prospective studies: inclusion criteria -- Prospective studies: results -- Candidates for TURBT -- TURBT as a prognostic factor -- TURBT and neoadjuvant chemotherapy -- Follow-up of patients treated with TURBT -- Summary -- Useful web links -- References -- Chapter 19 Partial cystectomy -- Introduction -- Indications -- Cancer in bladder diverticulum -- Adenocarcinoma and urachal tumors -- Other non-urothelial tumors -- Pre-operative considerations -- Surgical technique -- Perioperative complications -- Follow-up and outcomes -- Useful web links -- References -- Chapter 20 Integrating chemotherapy and radiotherapy for bladder cancer -- Introduction -- Selecting candidates for bladder-sparing therapy -- Chemotherapy concurrent with radiation therapy -- Neoadjuvant and adjuvant chemotherapy -- Local failure and salvage cystectomy -- Quality of life after bladder-sparing therapy -- Outcomes of bladder-sparing therapy -- The role for chemoradiation in non-muscle-invasive disease -- Future advances -- Conclusion -- Useful web links -- References -- Part IV Urinary tract reconstruction -- Chapter 21 Orthotopic neobladder -- Introduction -- Patient selection -- Basic tenets of pouch construction -- Surgical techniques for orthotopic diversion -- Results -- Conclusion -- Useful web links -- References -- Chapter 22 Continent cutaneous diversion -- General considerations about the choice of the type of continent urinary diversion -- Surgical techniques -- Ureteral implantation -- Complications -- Summary. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Useful web links -- References -- Chapter 23 Non-continent urinary diversion -- Introduction -- Patient preparation -- Surgical techniques -- Complications -- Quality of life (QoL) -- Follow-up of patients with conduit diversion -- Conclusions -- Useful Web links -- References -- Part V Treatment of regionally advanced and metastatic bladder cancer -- Chapter 24 Molecular determinants of chemotherapy response -- Introduction -- Potential biomarkers predicting response to chemotherapy - DNA repair enzymes, drug efflux proteins, and p53 -- Germline pharmacogenomics -- Gene expression models in urothelial cancer -- Conclusion -- References -- Chapter 25 Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer -- Introduction -- Cystectomy and chemoradiation series -- Rationale for chemotherapy prior to definitive surgery or chemoradiation therapy -- Randomized trials of neoadjuvant chemotherapy: data support a survival benefit -- Meta-analyses -- Barriers to implementation of neoadjuvant chemotherapy for bladder cancer -- Novel combinations of neoadjuvant therapy for bladder cancer -- Developing personalized neoadjuvant therapy: a paradigm to define risk of relapse and response to systemic therapy -- Summary -- Useful web links -- References -- Chapter 26 Adjuvant chemotherapy for invasive bladder cancer -- Introduction -- Adjuvant treatment -- Evidence summary -- Molecular biology and targeted therapies -- Conclusions and future directions -- Useful web links -- References -- Chapter 27 Treatment of metastatic bladder cancer -- Non-cisplatin-containing chemotherapy regimens -- Prognostic and predictive biomarkers in metastatic UC -- Second-line therapy -- Useful web links -- References -- Chapter 28 Treatment of poor risk patients -- Introduction -- What is poor risk urothelial cancer? -- Treatment of poor risk patients. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Conclusions. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Bladder -- Cancer -- Treatment. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Bladder -- Cancer -- Diagnosis. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Schoenberg, Mark P. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sternberg, Cora N. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Lerner, Seth P. |
| Title | Bladder Cancer |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2015 |
| International Standard Book Number | 9781118674840 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4037419">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4037419</a> |
| Public note | Click to View |
No items available.